February 12, 2024
Saol Therapeutics Receives Fast Track Designation for Treatment of Rare Mitochondrial Disease – Pyruvate Dehydrogenase Complex Deficiency (PDCD)
September 19, 2023
Saol Therapeutics Announces Completion of Enrollment in Both the Phase II COMPASS Osteoarthritis Knee Pain Trial and the Phase II RAISE Limb Spasticity Trial
March 16, 2023
Saol Therapeutics enhances its IP portfolio for Dichloroacetate (DCA; SL-1009) in Glioblastoma and Rare Pediatric Cancers
February 13, 2023
Saol Therapeutics Receives Golden Helix Innovation Award from the Center for Global Health Innovation
April 26, 2022
Saol Therapeutics and InformedDNA Partner to Offer Genetic Counseling to Patients with Rare Mitochondrial Disease
March 1, 2022
Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease
January 5, 2022
Amneal Acquires Saol Therapeutics’ Baclofen Franchise
December 6, 2021
Saol Therapeutics Announces FDA Approval of LYVISPAHTM (baclofen) Oral Granules and the Divesture of its Plasma-derived Hyperimmune Portfolio
January 11, 2019
Saol Therapeutics Announces that CDC Website has Been Updated to Reflect Wide Availability of VARIZIG® (Varicella Zoster Immune Globulin [Human])
August 16, 2018
VERIFY – Spasticity-related pain reduction and quality of life improvements seen in patients with post-stroke severe spasticity
January 11, 2018
VERIFY – New level 1 evidence for post-stroke severe spasticity